

Public Law 114–146
114th Congress

An Act

To expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.

Apr. 19, 2016
[S. 2512]

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Adding Zika Virus to the FDA Priority Review Voucher Program Act”.

Adding Zika
Virus to the FDA
Priority Review
Voucher Program
Act.
21 USC 301 note.

**SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW
VOUCHER PROGRAM TO ENCOURAGE TREATMENTS FOR
ZIKA VIRUS DISEASE.**

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—

- (1) by redesignating subparagraph (R) as subparagraph (S);
- (2) in subparagraph (Q), by striking “Filoviruses” and inserting “Filovirus Diseases”; and
- (3) by inserting after subparagraph (Q) the following:
“(R) Zika Virus Disease.”.

Approved April 19, 2016.

LEGISLATIVE HISTORY—S. 2512:

CONGRESSIONAL RECORD, Vol. 162 (2016):
Mar. 17, considered and passed Senate.
Apr. 12, considered and passed House.